Active Ingredient(s):Tildrakizumab-asmn FDA Approved: * March 20, 2018 Pharm Company: *MERCK SHARP DOHME Category:Immune System
Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.
Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immun...
* May have multiple approval dates, manufacturers, or labelers.